title: The accelerating role of Abelson murine leukemia virus in murine plasmacytoma development: in vitro infection of spleen cells generates donor-type tumors after transfer to pristane-treated BALB/c mice.
abstract: The role of Abelson murine leukemia virus (A-MuLV) in the accelerated development of murine plasmacytomas (PCs) (Potter et al., 1973: Science, 132, 592-594) was studied in a new experimental system. Spleen cells from pristane-treated or untreated BALB/c mice carrying Robertsonian 6;15 fusion chromosomes were infected in vitro with helper-free A-MuLV overnight and subsequently transplanted into the peritoneal cavity of pristane-treated or untreated BALB/c mice. Donor-derived PCs developed in 4 out of 76 pristane-treated recipients [latent periods: 38-82 (mean 51) days] that had received spleen cells from pristane-treated donors, and also in 2 out of 41 pristane-treated recipients that had received untreated donor-derived spleen cells (latent periods: 65 and 120 days). Three of the PCs in the former and both PCs in the latter group were tested for integration and expression of the v-abl gene, with positive results. This indicates that the spleen contains PC-precursor cells that can be activated by A-MuLV even before the impact of pristane. All 6 donor-origin PCs carried a translocation involving chromosome 15, band D2/3. Four of these corresponded to a typical 12;15 translocation, one was a variant 6;15 translocation and the 6th may represent a previously unidentified translocation between chromosome 15 and the lambda gene-carrying chromosome 16. No PCs developed among 29 pristane-untreated recipients that had received pristane-treated donor-derived spleen cells. In addition to PCs, monocytic tumors developed in 37 (26%) of all recipients. Their development was independent of pristane treatment of recipients but was particularly frequent in those who had received spleen cells from pristane-treated donors.
authors.affiliation: Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
authors.forename: G
authors.initials: G
authors.lastname: Weber
authors.forename: S
authors.initials: S
authors.lastname: Silva
authors.forename: M
authors.initials: M
authors.lastname: Babonits
authors.forename: F
authors.initials: F
authors.lastname: Wiener
authors.forename: G
authors.initials: G
authors.lastname: Klein
mesh_terms: D000011:Abelson murine leukemia virus / Q000472:pathogenicity*; D000818:Animals; D002869:Chromosome Aberrations; D009052:Leukemia Virus, Murine / Q000472:pathogenicity*; D051379:Mice; D008807:Mice, Inbred BALB C; D009857:Oncogenes; D010954:Plasmacytoma / Q000209:etiology* / Q000235:genetics; D013154:Spleen / Q000187:drug effects / Q000382:microbiology / Q000637:transplantation; D013729:Terpenes / Q000633:toxicity*
chemical_list: D013729:Terpenes; C009042:pristane